human oxytocin receptor

Epelsiban is a selective and orally bioavailable oxytocin receptor antagonist (pKi: 9.9 for human oxytocin receptor).

L-368,899 hydrochloride is an orally available and selective nonpeptide oxytocin receptor (OXTR) antagonist for the prevention of preterm labor.L-368,899 hydrochloride prevents oxytocin-induced anti-anomalous pain and anti-nausea, and may be useful for the study of depression.

d[Cha4]-AVP TFA is a potent and selective agonist for the vasopressin (AVP) V1b receptor, with a high affinity (K i of 1.2 nM). It shows greater selectivity for the V1b receptor over the V1a receptor, V2 receptor, and oxytocin receptors, demonstrating specificity in targeting the human V1b receptor [1] [2].

Pro8-Oxytocin TFA is a structurally modified oxytocin analog. Pro8-Oxytocin TFA is an agonist of the oxytocin receptor (OXTR) and has demonstrated greater potency than the endogenous ligand Leu8-Oxytocin in primate models, inducing stronger intracellular calcium mobilization and behavioral effects. Pro8-Oxytocin TFA is less effective than vasopressin (AVP) in eliciting responses in human AVPR1a, whereas it is more effective than AVP in eliciting responses in marmoset AVPR1a.

Potent and selective human vasopressin V1B receptor agonist (Ki values are 1.2, 151, 240 and 750 nM for V1B, V1A, Oxytocin and V2 receptors respectively). Stimulates ACTH and corticosterone secretion and exhibits negligible vasopressor activity in vivo.

d[Cha4]-AVP acetate is a potent and selective human vasopressin V1B receptor agonist (Ki values are 1.2, 151, 240 and 750 nM for V1B, V1A, Oxytocin and V2 receptors respectively). Stimulates ACTH and corticosterone secretion and exhibits negligible vasopr